Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production

Journal of Virology

Volumn 76, Issue 8, 2002, Pages 3881-3891

  Kaushik, Neerja ^a   Basu, Amartya ^a   Palumbo, Paul ^a   Myers, Rene L ^a   Pandey, Virendra N ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE DERIVATIVE; PEPTIDE; POLYAMIDE; TRANSPORTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONJUGATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS INHIBITION;

ANTI-HIV AGENTS; CELL MEMBRANE; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; JURKAT CELLS; PEPTIDE NUCLEIC ACIDS; PEPTIDES; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0036200148     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.8.3881-3891.2002     Document Type: Article

References (67)

1. New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected
2. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues
3. Tat transactivates the human immunodeficiency virus through a nascent RNA target
4. A small circular TAR RNA decoy specifically inhibits Tat activated HIV-1 transcription
5. Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type I in vitro
6. HIV inhibitors targeted at the reverse transcriptase
7. Stability of peptide nucleic acids in human serum and cellular extracts
8. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent
9. HIV-1 Tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure
10. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo
11. Tat-mediated delivery of heterologous proteins into cells
12. HIV-1 Tat trans-activation requires the loop sequence within tar
13. Activity of synthetic peptides from the Tat protein of HIV-1
14. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T
15. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery
16. Bactericidal antisense effects of peptide-PNA conjugates
17. Tat-responsive region RNA of human immunodeficiency virus type 1 stimulates protein synthesis in vivo and in vitro: Relationship between structure and function
18. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication
19. Antisense and antigene properties of peptide nucleic acids
20. Multifaceted activities of the HIV-1 transactivator of transcription, Tat
21. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 29,39-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro
22. In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations
23. Met
24. Tackling Tat
25. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs
26. Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase
27. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
28. Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus
29. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1
30. Antisense properties of duplex- and triplex-forming PNAs
31. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors
32. +-ATPase and reverses its inhibition by ouabain
33. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation
34. Stability of HIV type 1 proviral genomes that contain two distinct primer-binding sites
35. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment
36. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS
37. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioate
38. Cellular uptake of adamantyl conjugated peptide nucleic acids
39. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element
40. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-κB antagonists
41. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 29,39-dideoxynucleosides
42. Long-term inhibition of human T-lymphotropic virus type III/lymph-adenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 29,39-dideoxynucleosides in vitro
43. 39-Azido-39-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphoid nopathy-associated virus in vitro
44. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus
45. Regulation of mRNA accumulation by a human immunodeficiency virus transactivator protein
46. Peptide nucleic acids as therapeutic agents
47. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide
48. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions
49. Cell penetration by transportan
50. Galanin-based peptides, galparan and transportan, with receptor-dependent and independent activities
51. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo
52. Complete nucleotide sequence of the AIDS virus, HTLV-III
53. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 isease in vivo
54. Rational design of peptide-based HIV proteinase inhibitors
55. DNA sequencing with chain-terminating inhibitors
56. In vivo protein transduction: Delivery of a biologically active protein into the mouse
57. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain
58. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by Tat through the HIV-1 long terminal repeat
59. Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys
60. Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage
61. Lys
62. His
63. Use of polyethylene glycol-peptide conjugate in a competition gel shift assay for screening potential antagonists of HIV-1 Tat protein binding to TAR RNA
64. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism
65. Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells
66. Administration of 39-azido-39-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex